[Antiaggregants in the prevention of ischemic cardiopathy and systemic thromboembolism].
Recent studies, carried out to prevent thromboembolism in atrial fibrillation, showed a clear benefit of anticoagulant and antiplatelet drugs. Research is now focused to evaluate the antithrombotic effect of: low dose of anticoagulants and the combination of a therapeutic range of antiplatelet drugs and low dose of anticoagulants that may not need laboratory control. For the first time we also include patients with mitral stenosis and atrial fibrillation with the intention to reduce the dose of anticoagulants in the presence of a therapeutic antiplatelet treatment.
Pérez Gómez
F
F
Servicio de Cardiología, Hospital Universitario S. Carlos, Madrid.
Pérez Vizcaíno
F
F
D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D001792:Blood Platelets / Q000502:physiology; D006801:Humans; D017202:Myocardial Ischemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
D010975:Platelet Aggregation Inhibitors
Antiagregantes en la prevención de la cardiopatía isquémica y del tromboembolismo sistémico.